Why did COMPASS Pathways stock rise on 9 October?
Written after the close on
COMPASS Pathways +4.62%
Compass Pathways rose sharply as trial momentum builds. Over the last five trading days COMPASS Pathways ended roughly flat, lagging a healthcare sector that rose sharply and a market that rose clearly, as excitement over strong psilocybin trial data and a possible 2027 launch was offset by a large share offering that diluted existing holders. Psilocybin is the active compound in magic mushrooms, being tested here as a treatment for hard-to-treat depression. Watch the next earnings report in early November for updates on the regulatory filing.
Next report: · Add to calendar · Google Calendar